Gallacher Capital Management LLC Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Gallacher Capital Management LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,585 shares of the biopharmaceutical company’s stock after buying an additional 1,237 shares during the period. Gallacher Capital Management LLC’s holdings in Gilead Sciences were worth $452,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Sheets Smith Wealth Management lifted its position in Gilead Sciences by 85.2% during the fourth quarter. Sheets Smith Wealth Management now owns 42,701 shares of the biopharmaceutical company’s stock valued at $3,459,000 after buying an additional 19,641 shares in the last quarter. Avidian Wealth Solutions LLC boosted its position in Gilead Sciences by 3.3% during the 4th quarter. Avidian Wealth Solutions LLC now owns 8,148 shares of the biopharmaceutical company’s stock worth $660,000 after purchasing an additional 259 shares during the period. TCG Advisory Services LLC increased its holdings in Gilead Sciences by 28.3% in the 4th quarter. TCG Advisory Services LLC now owns 6,494 shares of the biopharmaceutical company’s stock valued at $526,000 after purchasing an additional 1,433 shares in the last quarter. Royal Fund Management LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $1,200,000. Finally, AJOVista LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $221,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $0.55 during midday trading on Friday, hitting $64.78. The company’s stock had a trading volume of 7,822,720 shares, compared to its average volume of 7,345,331. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. Gilead Sciences, Inc. has a 1-year low of $64.33 and a 1-year high of $87.86. The firm’s fifty day moving average price is $70.55 and its 200-day moving average price is $75.78. The firm has a market cap of $80.66 billion, a P/E ratio of 179.94, a P/E/G ratio of 1.30 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.37 earnings per share. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 3.74 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.75%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now owns 100,936 shares in the company, valued at approximately $7,386,496.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several analyst reports. Cantor Fitzgerald dropped their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Morgan Stanley lowered their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Finally, Mizuho cut their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and an average price target of $83.69.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.